- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03736109
Role of Copper-Albumin Complex in Treatment of Knee Osteoarthritis in Human
Role of Copper-Albumin Complex in Treatment of Knee Osteoarthritis in Human:a Pilot Prospective Comparative Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Osteoarthritis (OA) is a complex disease process involving the whole synovial joint. In OA articular cartilage is lost through a combination of degenerative and inflammatory phenomena, which are often accompanied by joint swelling, pain, stiffness and loss of joint mobility. The pathogenesis of OA is multifactorial and is considered to be a metabolically active process, predominantly due to the poor regenerative properties of articular cartilage after damage. The most commonly affected joint is the knee, and OA has a higher occurrence in older adults particularly women. Because patients generally present in the clinic after these symptoms of the illness develop, most treatment techniques for OA are designed to address these symptoms rather than cure the underlying disease. Current conservative treatments include lifestyle modification and pain medication (such as NSAIDs) which predominantly treat the illness (e.g., pain symptoms). There is also some promise in the use of chondroitin to decrease joint space narrowing in OA, thus treating the disease itself. Conversely, surgical intervention (partial or total joint replacement) is the preferred treatment method in end-stage disease leading to some relief of both the illness and disease.
Copper complexes can biochemically affect the cells and impinge upon metabolic pathways especially highly effective copper dependent enzymes, such as superoxide dismutase (SOD). It is predicted also that copper containing vitamins or biochemically active organic compounds such as amino acids and peptides or synthetic organic compounds in complexes can effectively scavenge superoxide radical. Additionally, recent studies showed that Cu (II) Bis (diethyldithiocarbamate) induced the expression of syndecan-4, a transmembrane heparan sulfate proteoglycan, in a dose- and time-dependent manner n via the activation of p38 mitogen-activated protein kinase. This submitted work has been designed to evaluate a copper chelating complex consisting of egg albumin and copper as one of the copper peptides that can be used as anti-inflammatory agent and chondroprotective in OA treatment that could be used as a substitute especially the currently used chondroprotective drugs are expensive and frequent using of drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), known to be aggressive agents for gastric ulcer development.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of both sexes and over 40 years of age diagnosed with unilateral or bilateral symptomatic OA of the knee who met the criteria of the American College of Rheumatology (ACR).
- Patients who were rated grade II or III on the Kellgren and Lawrence (K&L) radiological scale [19].
- Patients with symptomatic OA with a global mean pain in the knee >40 mm on a Visual Analogue Scale (VAS) for pain assessment.
Exclusion Criteria:
- Women who were pregnant or breastfeeding
- Patients who were grade I or IV on K&L radiological scale.
- Patients who have had a prosthesis replaced in the 12 months prior to inclusion.
- Obesity
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group I:
Thirty patients with knee osteoarthritis taking topical Copper-Albumin Complex cream
|
Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR.
In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
|
Group II:
Thirty patients with knee osteoarthritis taking oral chondroprotective drugs
|
Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR.
In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The mean difference of syndecan 4 expression and substance P before and after treatment
Time Frame: 2 months
|
better understanding the efficacy of the Copper-Albumin Complex treatment for knee osteoarthritis
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain improvement
Time Frame: 2 months
|
Visual Analog Score for pain
|
2 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Bai Z, Guo XH, Tang C, Yue ST, Shi L, Qiang B. Effects of Artesunate on the Expressions of Insulin-Like Growth Factor-1, Osteopontin and C-Telopeptides of Type II Collagen in a Rat Model of Osteoarthritis. Pharmacology. 2018;101(1-2):1-8. doi: 10.1159/000479160. Epub 2017 Sep 13.
- Duncan C, White AR. Copper complexes as therapeutic agents. Metallomics. 2012 Feb;4(2):127-38. doi: 10.1039/c2mt00174h. Epub 2011 Dec 20.
- Moller I, Gharbi M, Martinez Serrano H, Herrero Barbero M, Verges Milano J, Henrotin Y. Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients. BMC Musculoskelet Disord. 2016 Oct 6;17(1):416. doi: 10.1186/s12891-016-1268-4.
- Bay-Jensen AC, Thudium CS, Mobasheri A. Development and use of biochemical markers in osteoarthritis: current update. Curr Opin Rheumatol. 2018 Jan;30(1):121-128. doi: 10.1097/BOR.0000000000000467.
- Ding H, Wu T. Insulin-Like Growth Factor Binding Proteins in Autoimmune Diseases. Front Endocrinol (Lausanne). 2018 Aug 30;9:499. doi: 10.3389/fendo.2018.00499. eCollection 2018.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- osteoarthritis
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteo Arthritis Knee
-
University of PaviaNot yet recruitingLower Limb Arthroplasty: Effects of a Tele Prehabilitation Program With Indirect Electrostimulation.Osteo Arthritis Knee and Hip | Lower Limb ArthroplastyItaly
-
NHS LothianNot yet recruitingOsteo Arthritis Knee | Arthropathy of Knee | Arthritis KneeUnited Kingdom
-
Science and Research Centre KoperSlovenian Research AgencyCompletedOsteo Arthritis Knee | Knee ArthroplastySlovenia
-
Anchen Pharmaceuticals, IncNovum Pharmaceutical Research ServicesCompletedOsteo Arthritis of the KneeUnited States
-
Royal Infirmary of EdinburghUnknownOsteo Arthritis Knee | Arthroplasty, Replacement, KneeUnited Kingdom
-
Vastra Gotaland RegionActive, not recruiting
-
Smith & Nephew, Inc.Terminated
-
CorinRecruitingOsteo Arthritis Knee | Total Knee Arthroplasty | Total Knee Replacement | Knee DiseaseFrance
-
Boston UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Not yet recruiting
-
Mostafa BahaaRecruiting
Clinical Trials on Soluble and genetic biomarkers measurements
-
University Hospital, MontpellierRecruiting
-
University of CreteCompletedObstructive Sleep Apnea of AdultGreece
-
University of California, San DiegoRecruitingCarotid Artery Diseases | Neurocognitive DysfunctionUnited States
-
Cliniques universitaires Saint-Luc- Université...Recruiting
-
Assistance Publique - Hôpitaux de ParisFondation de Recherche sur l'Hypertension ArtérielleCompletedFibromuscular DysplasiaFrance, Belgium
-
Memorial Ankara HospitalUnknownHeart Diseases | Stroke | Thrombosis | Atrial Fibrillation | Genetic Predisposition
-
Necmettin Erbakan UniversityHacettepe University; Turkish Society of Medical OncologyRecruitingDietary Advanced Glycation End Products, Inflammation and Oxidative Stress in Breast Cancer PatientsBreast Cancer | FemaleTurkey
-
Ya-Wei XuCompletedHeart Failure With Preserved Ejection Fraction
-
Graminex LLCKGK Science Inc.CompletedUrinary IncontinenceCanada
-
Purdue UniversityTate and Lyle Ingredients Americas LLCCompleted